Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A botanical herbal combination product developed by Shengjing Hospital of China Medical University for the treatment of plasma cell mastitis (PCM). The formulation consists of eight traditional Chinese medicinal herbs: Taraxacum, Fructus forsythiae, Honeysuckle, Uniflower swisscentaury root, Herba violae, Danshen, Astragalus, and Liquorice. It is administered orally as granules. The drug is designed to regulate the immune system, addressing the immune dysregulation characteristic of PCM. The formulation was identified using a knowledge graph architecture designed to select herbal combinations based on target-hitting rates and phenotype relativeness for immunotherapy. A Phase 2 clinical trial (NCT05530226) evaluated its efficacy and safety in women with PCM.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shengjing Hospital Plasma Cell Mastitis Herbal Formula.